Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INL-001 in pediatric inguinal hernia repair
NCT03262688Phase 3Unknown
- Sponsor
- Innocoll
- Start
- Jun 2017
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by Innocoll. Primary endpoints: Adverse events at 30 days, Blood pressure (systolic/diastolic) and 6 more. Status: unknown.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03262688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262688.